Dr. Anastassios G. Pittas chief of Endocrinology Diabetes and Metabolism at Tufts Medical Center

A new weight-loss treatment is being heralded by some health experts as "groundbreaking," and a potential "game changer" in the growing epidemic of obesity. ABC News reports that Semaglutide, an injectable drug made by the pharmaceutical company Novo Nordisk, was approved Friday by the Food and Drug Administration (FDA), for patients struggling with chronic obesity. "We don't use those terms lightly," Northwestern University Feinberg School of Medicine professor Dr. Robert […]